Drugs / CKD-351
last change May 2022 re-read 2 minutes ago

CKD-351

Developed for
ocular hypertension · open-angle glaucoma
Investigated by
Chong Kun Dang Pharmaceutical

Trials 1 · a red edge is where a trial was stopped

20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT03762369 Dec 2018 → Feb 2022 ocular hypertension, open-angle glaucoma Chong Kun Dang Pharmaceutical Unknown No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CKD-351 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03762369